英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Philol查看　Philol　在百度字典中的解释百度英翻中〔查看〕
Philol查看　Philol　在Google字典中的解释Google英翻中〔查看〕
Philol查看　Philol　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Imetelstat Sodium - NCI - National Cancer Institute
    Imetelstat sodium works by blocking the activity of an enzyme called telomerase, which is found at high levels in cells that divide rapidly, including cancer cells Blocking this enzyme keeps cancer cells from dividing and causes them to die Imetelstat sodium is a type of targeted therapy called an enzyme inhibitor
  • Imetelstat: A First-in-Class Telomerase Inhibitor for the Treatment of . . .
    Imetelstat is a first-in-class, direct, and competitive inhibitor of telomerase enzymatic activity that selectively induces apoptosis of malignant clones and allows for recovery of erythropoiesis
  • Oncology Drug Reference Sheet: Imetelstat - ons. org
    In June 2024, imetelstat (Rytelo™) became the first telomerase inhibitor approved by the U S Food and Drug Administration (FDA) Imetelstat treats low- to intermediate-risk myelodysplastic syndromes in adults with transfusion-dependent anemia
  • Imetelstat (Rytelo™) - OncoLink
    Imetelstat (Rytelo™) is a telomerase inhibitor How To Take Imetelstat Imetelstat is given intravenously (into a vein) The amount given and schedule are based on your size You will have your labs checked before each dose The results of your labs help guide your treatment plan You will be given diphenhydramine (Benadryl) and hydrocortisone (steroid) before your infusion to help lessen an
  • What are the benefits of Imetelstat? | Imetelstat
    The primary benefit of imetelstat lies in its targeted approach to cancer treatment By directly inhibiting telomerase, it offers a novel treatment avenue that is distinct from traditional chemotherapy and radiation This targeted therapy approach has the potential to minimize side effects while maximizing therapeutic efficacy Additionally, imetelstat has shown the ability to overcome
  • FDA approves imetelstat for low- to intermediate-1 risk myelodysplasti
    On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk
  • New Treatment Approved for Certain Patients Living With Myelodysplastic . . .
    The U S Food and Drug Administration has approved imetelstat (known commercially as RYTELO) to treat some patients with the rare blood cancer, myelodysplastic syndromes (MDS) Amer Zeidan, MBBS, chief of hematologic malignancies at Yale Cancer Center and associate professor of internal medicine (Hematology) at Yale School of Medicine, was one of the investigators on the IMerge phase III trial
  • Telomerase inhibitor imetelstat kills AML cells via lipid ROS and . . .
    Imetelstat is a first-in-class telomerase inhibitor with efficacy in a number of blood cancers Intriguingly, telomere lengths do not predict patient responses to imetelstat We now show that
  • A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in . . .
    Telomerase inhibition leads to loss of a cancer cell's ability to maintain telomere length (TL), resulting in cell-cycle arrest, apoptosis or senescence In June 2024, imetelstat became the first telomerase inhibitor to be approved by the FDA and is indicated for the treatment of patients with transfusion-dependent lower-risk (LR) MDS who are
  • Imetelstat: A First-in-Class Telomerase Inhibitor for the Treatment of . . .
    Abstract Imetelstat is a first-in-class, direct, and competitive inhibitor of telom-erase enzymatic activity that selectively induces apoptosis of ma-lignant clones and allows for recovery of erythropoiesis Imetelstat was approved by the United States Food and Drug Administration in June 2024 and the European Medicines Agency in March 2025 for the treatment of certain patients with lower-risk





中文字典-英文字典  2005-2009